Clinical Trials Browser

Phase 2 × Active not recruiting × lutetium Lu 177 dotatate × Clear all

NCT05724108 2026-03-19

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors

NCT03971461 2026-03-11

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

Phase 2 Active not recruiting

Meningioma

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT03457948 2025-09-03

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Phase 2 Active not recruiting

Neuroendocrine Tumors

NCT05247905 2025-04-02

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2 Active not recruiting

Adenoma, Islet Cell

NCT02754297 2024-08-21

P-PRRT

Phase 2 Active not recruiting

Carcinoid Tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors